Ipca Laboratories growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+7.9%+15.6%
EBITDA+14.6%+28.8%
Net Income+50.8%+35.2%
EPS (adj.)+54.7%+34.3%
Total Assets+5.2%+12.8%
Total Equity+13.6%+17.2%
Free Cash Flow−10.3%+16.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

IPCALAB₹1,930.50

Ipca Laboratories Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMJBCHEPHARMABBOTINDIAAJANTPHARMANTHEMGLAXOMEDANTAMcap ₹48,977 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+7.9+15.6
EBITDA+14.6+28.8
Net Income+50.8+35.2
EPS (adj.)+54.7+34.3
Total Assets+5.2+12.8
Total Equity+13.6+17.2
Free Cash Flow-10.3+16.3
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.